What is the 13F Pro Quality Score for ENGN?

13F Pro ranks enGene Therapeutics Inc. (ENGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ENGN's current score at https://13fpro.ai/company/ENGN (free sign-up required for the full ranking).

Which hedge funds own the most ENGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ENGN include FCPM III SERVICES B.V., BML Capital Management,, Siren, L.L.C.. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/ENGN as soon as new 13F filings post.

Where does 13F Pro source ENGN data?

All enGene Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. enGene Therapeutics Inc. files with the SEC under CIK 1980845. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ENGN in?

enGene Therapeutics Inc. (ENGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What are ENGN's largest expenses?

enGene Therapeutics Inc.'s latest 10-Q reports these as the largest expense items: Research and development ($20.1M, -11% QoQ); General and administrative ($13.9M, +89% QoQ); Interest expense ($0.8M, +11% QoQ). Sourced directly from SEC EDGAR filing text for Q3 FY2026 (quarter ended July 31, 2026).

How often is ENGN research updated on 13F Pro?

ENGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

enGene Therapeutics Inc.(ENGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1980845 ENGN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ENGN Stock Analysis & AI Quality Score

Data updated 2026-09-08

AI stock analysis and institutional research for enGene Therapeutics Inc. (ENGN), a Healthcare sector company. ENGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), enGene Therapeutics Inc. reports net income of $-32.5M, free cash flow of $-18.9M. Top institutional holders of ENGN by reported 13-F value include FCPM III SERVICES B.V., BML Capital Management, Siren, L.L.C., based on the most recent SEC filings. ENGN trades on the Nasdaq exchange and files with the SEC under CIK 1980845. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ENGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for enGene Therapeutics Inc. directly from SEC EDGAR.

What's Driving ENGN's Business? Latest 10-Q Breakdown

✓ 15/15 datapoints verified

AI-extracted from enGene Therapeutics Inc.'s 10-Q filed 2026-09-08 — Q3 FY2026 (quarter ended July 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Clinical-stage biotech enGene reported $20.1M R&D and $13.9M G&A expenses for Q3 2026, reducing workforce by 50% to preserve $266.3M in cash and plan Q4 2026 BLA submission for detalimogene.

Biggest Revenue Drivers

Largest Expense Items

Research and development$20.1M-11% QoQ

Lower manufacturing costs for detalimogene; offset by restructuring-related personnel severance and accelerated vesting.

General and administrative$13.9M+89% QoQ

Higher personnel costs ($10.8M) driven by June 2026 workforce reduction severance and stock-based compensation acceleration.

Interest expense$0.8M+11% QoQ

Interest on $25.0M term loan drawn January 2026 under Second Amended Loan Agreement with Hercules.

Margins: Company is pre-revenue with gross margins not applicable. Operating loss of $34.0M for Q3 reflects ongoing R&D and restructuring charges, partially offset by $2.4M interest income on $266.3M in cash and marketable securities.

Watch Items from the Filing

50% workforce reduction announced June 2026; company estimates $5.6–$6.1M restructuring costs plus $5.0–$5.5M stock-based compensation expense through Q4 2026.
Accumulated deficit of $464.5M as of July 31, 2026; company is pre-revenue and expects cash sufficient for 12+ months but will need additional funding for continued development.
Detalimogene pivotal Phase 2 cohort showed 54% any-time complete response rate but only 13.3% at 12 months; FDA meeting and BLA submission targeted Q4 2026.
New cohort testing detalimogene with surfactant rinse (polidocanol) added to LEGEND trial; company suspended enrollment in other cohorts to preserve cash pending FDA feedback.
Chief Medical Officer Hussein Sweiti resigned June 2026; interim CMO appointed. Company incurred $0.7M severance and $1.2M accelerated stock vesting for this departure.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Net Income

Q2 2026

$-32.5M

Free Cash Flow

Q2 2026

$-18.9M

ROIC

Q2 2026

-59.1%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

-112.7% YoY

$-117.3MFY 2025

FY22 $-24.5MFY23 $-99.9MFY24 $-55.1MFY25 $-117.3M

Operating Income

-97.7% YoY

$-123.2MFY 2025

FY22 $-19.4MFY23 $-26.1MFY24 $-62.3MFY25 $-123.2M

EPS (Diluted)

+56.8% YoY

$2.29FY 2025

FY22 $22.15FY23 $75.61FY24 $1.46FY25 $2.29

Total Assets

-28.8% YoY

$221.5MFY 2025

FY22 $23.9MFY23 $87.0MFY24 $311.2MFY25 $221.5M

Op. Cash Flow

-105.5% YoY

$-99.2MFY 2025

FY22 $-17.6MFY23 $-24.7MFY24 $-48.3MFY25 $-99.2M

Free Cash Flow

-104.7% YoY

$-100.7MFY 2025

FY22 $-17.7MFY23 $-25.1MFY24 $-49.2MFY25 $-100.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Income	$-117.3M -112.7%	$-55.1M +44.8%	$-99.9M -308.5%	$-24.5M	—
Operating Income	$-123.2M -97.7%	$-62.3M -139.1%	$-26.1M -34.1%	$-19.4M	—
EPS (Diluted)	$2.29 +56.8%	$1.46 -98.1%	$75.61 +241.4%	$22.15	—
Total Assets	$221.5M -28.8%	$311.2M +257.8%	$87.0M +263.7%	$23.9M	—
Operating Cash Flow	$-99.2M -105.5%	$-48.3M -95.1%	$-24.7M -40.6%	$-17.6M	—
Free Cash Flow	$-100.7M -104.7%	$-49.2M -96.3%	$-25.1M -41.2%	$-17.7M	—

Get alerted when ENGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for enGene Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ENGN

FCPM III SERVICES B.V.
$16.7M9,632,561 sh
BML Capital Management, LLC
$11.5M6,669,908 sh
Siren, L.L.C.
$10.8M6,256,662 sh
PERCEPTIVE ADVISORS LLC
$8.3M4,822,169 sh
AMERIPRISE FINANCIAL INC
$4.6M2,675,876 sh
Nextech Invest, Ltd.
$4.0M2,324,943 sh
ADAR1 Capital Management, LLC
$3.6M2,104,986 sh
Vestal Point Capital, LP
$2.9M1,667,430 sh
ACORN CAPITAL ADVISORS, LLC
$2.2M1,271,257 sh
Peapod Lane Capital LLC
$1.9M1,102,149 sh

Fund	Value	Shares
FCPM III SERVICES B.V.	$16.7M	9,632,561
BML Capital Management, LLC	$11.5M	6,669,908
Siren, L.L.C.	$10.8M	6,256,662
PERCEPTIVE ADVISORS LLC	$8.3M	4,822,169
AMERIPRISE FINANCIAL INC	$4.6M	2,675,876
Nextech Invest, Ltd.	$4.0M	2,324,943
ADAR1 Capital Management, LLC	$3.6M	2,104,986
Vestal Point Capital, LP	$2.9M	1,667,430
ACORN CAPITAL ADVISORS, LLC	$2.2M	1,271,257
Peapod Lane Capital LLC	$1.9M	1,102,149

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ENGN on your watchlist

Track score changes the day enGene Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ENGN a good stock to buy?

13F Pro's AI-powered analysis of enGene Therapeutics Inc. (ENGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ENGN are available on the ENGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ENGN is classified as a small company.

Which hedge funds own ENGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ENGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of enGene Therapeutics Inc.'s investment landscape.